share_log

康宁杰瑞制药-B(09966.HK):于2024年AACR年会呈列的JSKN003用于治疗HER2表达晚期实体瘤的I期临床研究的最新结果

Corning Jerry Pharmaceutical-B (09966.HK): The latest results of the Phase I clinical study of JSKN003 for the treatment of advanced solid tumors with advanced HER2 expression presented at the 2024 AACR Annual Meeting

Gelonghui Finance ·  Apr 9 18:21

Gelonghui, April 10, 丨 Corning Jerry Pharmaceutical-B (09966.HK) announced that the results of the JSKN003 Phase I clinical study (study number: JSKN003-101) (“JSKN003-101”) for the treatment of patients with advanced/metastatic solid tumors (poster board number: 7; abstract number: CT179) were presented during the poster presentation period at the 2024 AACR Annual Conference held from April 5 to April 10, 2024.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment